Skip to main content

AMRX Amneal Pharmaceuticals, Inc.

Healthcare

19.57

Close 10/13

Open
20.05
High
20.15
Low
19.45
Prev close
20.03
Volume
3.5M
P/E
40.1
P/B
189.3
52W 9.56 21.18
Loading candles…

Is Amneal Pharmaceuticals, Inc. a buy? Fundamentals and valuation first

As of 2026-10-13

Quality: Good, Growth: Good, Momentum: Strong, Risk / liquidity: Good; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but Price / book is Expensive.
TTM P/E 40.14 77th percentile Pricey
Price / book 189.25 99th percentile Expensive
Free-cash-flow yield (%) 1.33 50th percentile Good
Quality Good ROE, TTM is Top, but FCF margin, TTM is Average.
ROE, TTM (%) 477.24 98th percentile Top
Operating margin, TTM (%) 12.63 61th percentile Good
FCF margin, TTM (%) 2.67 45th percentile Average
Growth Good Diluted EPS growth, TTM YoY is Top; Revenue growth, TTM YoY is Good.
Revenue growth, TTM YoY (%) 9.28 59th percentile Good
Diluted EPS growth, TTM YoY (%) 7,286.36 99th percentile Top
Momentum Strong All 2 indicators are Top.
60-day return (%) 11.83 83th percentile Top
240-day return (%) 90.18 94th percentile Top
Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 64,187,822 83th percentile Top
60-day annualized volatility (%) 39.58 45th percentile Good

Amneal Pharmaceuticals, Inc. (AMRX) today

1 quant signals active · As of 2026-10-13

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

Amneal Pharmaceuticals, Inc. (AMRX) peers and tracking

Watchlist

This page refreshes daily after the close. Add Amneal Pharmaceuticals, Inc. to your watchlist to track signal changes on your next visit.

Amneal Pharmaceuticals, Inc. (AMRX) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 89.46%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

24 historical occurrences (since 2017-06-08)
Average forward return after Top-quintile 6-month momentum。20-day: Win 58.3%, Sample 24, Median +3.32%, Excess -0.56%, Beat mkt rate 45.8%；60-day: Win 60.9%, Sample 23, Median +12.89%, Excess +3.9%, Beat mkt rate 60.9%；120-day: Win 59.1%, Sample 22, Median +7.13%, Excess -1.38%, Beat mkt rate 50%

120 days after: historical avg +7.17%

20-day +2.23%
60-day +8.07%
120-day +7.17%
20-day
60-day
120-day
Win
58.3%
60.9%
59.1%
Sample
24
23
22
Median
+3.32%
+12.89%
+7.13%
Excess
-0.56%
+3.9%
-1.38%
Beat mkt rate
45.8%
60.9%
50%

Over 22 occurrences, 120-day forward avg gained 7.17%, lagged the market by 1.38 pts; win rate 59.1%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 0Insufficient data
20-40 You are here0Insufficient data
40-60 0Insufficient data
60-80 0Insufficient data
80-100 0Insufficient data

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 40.14, placing it in the 35.8 own-history percentile, inside the 20-40 bucket.

More history: Valuation × momentum analogs, Market-wide momentum baseline, Signals not active now

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
Insufficient data
(0d)
Now
Insufficient data
(0d)
Insufficient data
(0d)
60-day momentum down
Insufficient data
(0d)
Insufficient data
(0d)
Insufficient data
(0d)

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 98,272 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.50%, a 58.4% positive-return rate, and +3.15 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

18 times historically; 60-day forward avg +6.2%, win rate 58.8%, beating the market by +2.7 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

6 times historically; 60-day forward avg -13.78%, win rate 50%, beating the market by -18.39 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

27 times historically; 60-day forward avg +11.05%, win rate 72%, beating the market by +5.84 pts on average.

Continue researching Amneal Pharmaceuticals, Inc. with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.